Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts

Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015–2027): a nationwide, population-based study

“…By contrast to IBD, the absence of licensed medical therapy for PSC means that the rising prevalence is likely a consequence of accelerated incidence. 1 The fact that PSC-IBD prevalence is increasing at a rate that exceeds IBD alone also supports the presence of additional aetiological drivers, 35 , 36 which need to be studied, tested and confirmed. Increased awareness of PSC amongst physicians who treat IBD is also important, particularly for sub-clinical presentations of disease, given the heightened risks of malignancy.…”